Compare Gemini Space Station Inc (GEMI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Sana Biotechnology Inc — how do they compare? Gemini Space Station Inc trades at $4.16 (market cap $512.05M), while Sana Biotechnology Inc trades at $3.85 (market cap $1.13B). The key difference: Sana Biotechnology Inc is far larger — about 2.2× Gemini Space Station Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| GEMI | SANA | |
|---|---|---|
Market Cap | $512.05M | $1.13B |
Sector | Technology | Health |
52-Week High | $32.52 | $5.92 |
52-Week Low | $3.90 | $2.68 |
Enterprise Value | $502.04M | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.085, down 0.61% on the day, with technical indicators showing a bearish trend. The company reported significant losses with a net income margin of -278.9% in 2025 and has missed earnings expectations for three consecutive quarters. Recent developments include a $100 million investment from Winklevoss Capital and the launch of commission-free stock trading as part of its super app strategy.
Despite analyst consensus pointing to upside potential with a $6.33 price target, GEMI faces substantial execution risks amid ongoing securities lawsuits and persistent negative profitability. The stock presents high-risk speculative appeal for investors betting on the company's financial infrastructure transformation, but current fundamentals remain deeply concerning.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
